Clinical Trial Update: A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination of ibrutinib and short-course fludarabine in treatment-naive chronic lymphocytic leukemia. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-10-08